Monkeypox Virus Cross-Neutralizing Antibodies in Clinical Trial Participants Vaccinated With Modified Vaccinia Virus Ankara Encoding Middle East Respiratory Syndrome–Coronavirus Spike Protein

Modified vaccinia virus Ankara (MVA) is used as a vaccine against monkeypox virus and as a viral vaccine vector. MVA-MERS-S is a vaccine candidate against Middle East respiratory syndrome (MERS)–associated coronavirus. Here, we report that cross-reactive monkeypox virus neutralizing antibodies were...

Descripción completa

Detalles Bibliográficos
Autores principales: Raadsen, Matthijs P, Dahlke, Christine, Fathi, Anahita, Lamers, Mart M, van den Doel, Petra, Zaeck, Luca M, van Royen, Martin E, de Bruin, Erwin, Sikkema, Reina, Koopmans, Marion, van Gorp, Eric C M, Sutter, Gerd, de Vries, Rory D, Addo, Marylyn M, Haagmans, Bart L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469103/
https://www.ncbi.nlm.nih.gov/pubmed/36857443
http://dx.doi.org/10.1093/infdis/jiad052
_version_ 1785099371235246080
author Raadsen, Matthijs P
Dahlke, Christine
Fathi, Anahita
Lamers, Mart M
van den Doel, Petra
Zaeck, Luca M
van Royen, Martin E
de Bruin, Erwin
Sikkema, Reina
Koopmans, Marion
van Gorp, Eric C M
Sutter, Gerd
de Vries, Rory D
Addo, Marylyn M
Haagmans, Bart L
author_facet Raadsen, Matthijs P
Dahlke, Christine
Fathi, Anahita
Lamers, Mart M
van den Doel, Petra
Zaeck, Luca M
van Royen, Martin E
de Bruin, Erwin
Sikkema, Reina
Koopmans, Marion
van Gorp, Eric C M
Sutter, Gerd
de Vries, Rory D
Addo, Marylyn M
Haagmans, Bart L
author_sort Raadsen, Matthijs P
collection PubMed
description Modified vaccinia virus Ankara (MVA) is used as a vaccine against monkeypox virus and as a viral vaccine vector. MVA-MERS-S is a vaccine candidate against Middle East respiratory syndrome (MERS)–associated coronavirus. Here, we report that cross-reactive monkeypox virus neutralizing antibodies were detectable in only a single study participant after the first dose of MVA-MERS-S vaccine, in 3 of 10 after the second dose, and in 10 of 10 after the third dose.
format Online
Article
Text
id pubmed-10469103
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-104691032023-09-01 Monkeypox Virus Cross-Neutralizing Antibodies in Clinical Trial Participants Vaccinated With Modified Vaccinia Virus Ankara Encoding Middle East Respiratory Syndrome–Coronavirus Spike Protein Raadsen, Matthijs P Dahlke, Christine Fathi, Anahita Lamers, Mart M van den Doel, Petra Zaeck, Luca M van Royen, Martin E de Bruin, Erwin Sikkema, Reina Koopmans, Marion van Gorp, Eric C M Sutter, Gerd de Vries, Rory D Addo, Marylyn M Haagmans, Bart L J Infect Dis Brief Report Modified vaccinia virus Ankara (MVA) is used as a vaccine against monkeypox virus and as a viral vaccine vector. MVA-MERS-S is a vaccine candidate against Middle East respiratory syndrome (MERS)–associated coronavirus. Here, we report that cross-reactive monkeypox virus neutralizing antibodies were detectable in only a single study participant after the first dose of MVA-MERS-S vaccine, in 3 of 10 after the second dose, and in 10 of 10 after the third dose. Oxford University Press 2023-03-01 /pmc/articles/PMC10469103/ /pubmed/36857443 http://dx.doi.org/10.1093/infdis/jiad052 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Brief Report
Raadsen, Matthijs P
Dahlke, Christine
Fathi, Anahita
Lamers, Mart M
van den Doel, Petra
Zaeck, Luca M
van Royen, Martin E
de Bruin, Erwin
Sikkema, Reina
Koopmans, Marion
van Gorp, Eric C M
Sutter, Gerd
de Vries, Rory D
Addo, Marylyn M
Haagmans, Bart L
Monkeypox Virus Cross-Neutralizing Antibodies in Clinical Trial Participants Vaccinated With Modified Vaccinia Virus Ankara Encoding Middle East Respiratory Syndrome–Coronavirus Spike Protein
title Monkeypox Virus Cross-Neutralizing Antibodies in Clinical Trial Participants Vaccinated With Modified Vaccinia Virus Ankara Encoding Middle East Respiratory Syndrome–Coronavirus Spike Protein
title_full Monkeypox Virus Cross-Neutralizing Antibodies in Clinical Trial Participants Vaccinated With Modified Vaccinia Virus Ankara Encoding Middle East Respiratory Syndrome–Coronavirus Spike Protein
title_fullStr Monkeypox Virus Cross-Neutralizing Antibodies in Clinical Trial Participants Vaccinated With Modified Vaccinia Virus Ankara Encoding Middle East Respiratory Syndrome–Coronavirus Spike Protein
title_full_unstemmed Monkeypox Virus Cross-Neutralizing Antibodies in Clinical Trial Participants Vaccinated With Modified Vaccinia Virus Ankara Encoding Middle East Respiratory Syndrome–Coronavirus Spike Protein
title_short Monkeypox Virus Cross-Neutralizing Antibodies in Clinical Trial Participants Vaccinated With Modified Vaccinia Virus Ankara Encoding Middle East Respiratory Syndrome–Coronavirus Spike Protein
title_sort monkeypox virus cross-neutralizing antibodies in clinical trial participants vaccinated with modified vaccinia virus ankara encoding middle east respiratory syndrome–coronavirus spike protein
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469103/
https://www.ncbi.nlm.nih.gov/pubmed/36857443
http://dx.doi.org/10.1093/infdis/jiad052
work_keys_str_mv AT raadsenmatthijsp monkeypoxviruscrossneutralizingantibodiesinclinicaltrialparticipantsvaccinatedwithmodifiedvacciniavirusankaraencodingmiddleeastrespiratorysyndromecoronavirusspikeprotein
AT dahlkechristine monkeypoxviruscrossneutralizingantibodiesinclinicaltrialparticipantsvaccinatedwithmodifiedvacciniavirusankaraencodingmiddleeastrespiratorysyndromecoronavirusspikeprotein
AT fathianahita monkeypoxviruscrossneutralizingantibodiesinclinicaltrialparticipantsvaccinatedwithmodifiedvacciniavirusankaraencodingmiddleeastrespiratorysyndromecoronavirusspikeprotein
AT lamersmartm monkeypoxviruscrossneutralizingantibodiesinclinicaltrialparticipantsvaccinatedwithmodifiedvacciniavirusankaraencodingmiddleeastrespiratorysyndromecoronavirusspikeprotein
AT vandendoelpetra monkeypoxviruscrossneutralizingantibodiesinclinicaltrialparticipantsvaccinatedwithmodifiedvacciniavirusankaraencodingmiddleeastrespiratorysyndromecoronavirusspikeprotein
AT zaecklucam monkeypoxviruscrossneutralizingantibodiesinclinicaltrialparticipantsvaccinatedwithmodifiedvacciniavirusankaraencodingmiddleeastrespiratorysyndromecoronavirusspikeprotein
AT vanroyenmartine monkeypoxviruscrossneutralizingantibodiesinclinicaltrialparticipantsvaccinatedwithmodifiedvacciniavirusankaraencodingmiddleeastrespiratorysyndromecoronavirusspikeprotein
AT debruinerwin monkeypoxviruscrossneutralizingantibodiesinclinicaltrialparticipantsvaccinatedwithmodifiedvacciniavirusankaraencodingmiddleeastrespiratorysyndromecoronavirusspikeprotein
AT sikkemareina monkeypoxviruscrossneutralizingantibodiesinclinicaltrialparticipantsvaccinatedwithmodifiedvacciniavirusankaraencodingmiddleeastrespiratorysyndromecoronavirusspikeprotein
AT koopmansmarion monkeypoxviruscrossneutralizingantibodiesinclinicaltrialparticipantsvaccinatedwithmodifiedvacciniavirusankaraencodingmiddleeastrespiratorysyndromecoronavirusspikeprotein
AT vangorpericcm monkeypoxviruscrossneutralizingantibodiesinclinicaltrialparticipantsvaccinatedwithmodifiedvacciniavirusankaraencodingmiddleeastrespiratorysyndromecoronavirusspikeprotein
AT suttergerd monkeypoxviruscrossneutralizingantibodiesinclinicaltrialparticipantsvaccinatedwithmodifiedvacciniavirusankaraencodingmiddleeastrespiratorysyndromecoronavirusspikeprotein
AT devriesroryd monkeypoxviruscrossneutralizingantibodiesinclinicaltrialparticipantsvaccinatedwithmodifiedvacciniavirusankaraencodingmiddleeastrespiratorysyndromecoronavirusspikeprotein
AT addomarylynm monkeypoxviruscrossneutralizingantibodiesinclinicaltrialparticipantsvaccinatedwithmodifiedvacciniavirusankaraencodingmiddleeastrespiratorysyndromecoronavirusspikeprotein
AT haagmansbartl monkeypoxviruscrossneutralizingantibodiesinclinicaltrialparticipantsvaccinatedwithmodifiedvacciniavirusankaraencodingmiddleeastrespiratorysyndromecoronavirusspikeprotein

Ejemplares similares